中国医师杂志
中國醫師雜誌
중국의사잡지
Journal of Chinese Physician
2015年
9期
1347-1350
,共4页
利钠肽,脑/投药和剂量%半乳糖凝集素3/投药和剂量%心力衰竭/药物疗法
利鈉肽,腦/投藥和劑量%半乳糖凝集素3/投藥和劑量%心力衰竭/藥物療法
리납태,뇌/투약화제량%반유당응집소3/투약화제량%심력쇠갈/약물요법
Natriuretic peptide,brain/AD%Galectin 3/AD%Heart failure/DT
目的 评价N端B型脑钠肽前体(NT-proBNP)联合半乳糖凝集素3(galectin-3)对慢性心力衰竭(CHF)患者预后的价值.方法 测定92例CHF患者入院和出院时血NT-proBNP和galectin-3水平,观察、随访出院后16个月内因心力衰竭再发住院率及死亡率.结果 美国纽约心脏病协会(NYHA)心功能Ⅰ、Ⅱ、Ⅲ、Ⅳ级患者NT-proBNP水平分别为(351.6±467.5)pg/ml、(493.2±411.7) pg/ml、(1 289.6±737.8) pg/ml、(2719.2±1 044.1)pg/ml;galectin-3水平分别为(12.23±6.12) ng/ml、(13.59±5.46) ng/ml、(21.18±7.44) ng/ml、(26.61±8.82) ng/mlo NT-proBNP和galec-tin-3的水平随患者心功能的降低而升高.出院时NT-proBNP或galectin-3仍高于正常的患者在随访中发生心力衰竭再发住院或死亡的几率明显高于正常的患者;而出院时NT-proBNP和galectin-3均增高的患者其预后明显较其中一项值增高的患者差.结论 NT-proBNP和galectin-3两者均是心力衰竭患者不良预后的独立预测指标,galectin-3联合NT-proBNP可以更好地评估CHF患者的预后.
目的 評價N耑B型腦鈉肽前體(NT-proBNP)聯閤半乳糖凝集素3(galectin-3)對慢性心力衰竭(CHF)患者預後的價值.方法 測定92例CHF患者入院和齣院時血NT-proBNP和galectin-3水平,觀察、隨訪齣院後16箇月內因心力衰竭再髮住院率及死亡率.結果 美國紐約心髒病協會(NYHA)心功能Ⅰ、Ⅱ、Ⅲ、Ⅳ級患者NT-proBNP水平分彆為(351.6±467.5)pg/ml、(493.2±411.7) pg/ml、(1 289.6±737.8) pg/ml、(2719.2±1 044.1)pg/ml;galectin-3水平分彆為(12.23±6.12) ng/ml、(13.59±5.46) ng/ml、(21.18±7.44) ng/ml、(26.61±8.82) ng/mlo NT-proBNP和galec-tin-3的水平隨患者心功能的降低而升高.齣院時NT-proBNP或galectin-3仍高于正常的患者在隨訪中髮生心力衰竭再髮住院或死亡的幾率明顯高于正常的患者;而齣院時NT-proBNP和galectin-3均增高的患者其預後明顯較其中一項值增高的患者差.結論 NT-proBNP和galectin-3兩者均是心力衰竭患者不良預後的獨立預測指標,galectin-3聯閤NT-proBNP可以更好地評估CHF患者的預後.
목적 평개N단B형뇌납태전체(NT-proBNP)연합반유당응집소3(galectin-3)대만성심력쇠갈(CHF)환자예후적개치.방법 측정92례CHF환자입원화출원시혈NT-proBNP화galectin-3수평,관찰、수방출원후16개월내인심력쇠갈재발주원솔급사망솔.결과 미국뉴약심장병협회(NYHA)심공능Ⅰ、Ⅱ、Ⅲ、Ⅳ급환자NT-proBNP수평분별위(351.6±467.5)pg/ml、(493.2±411.7) pg/ml、(1 289.6±737.8) pg/ml、(2719.2±1 044.1)pg/ml;galectin-3수평분별위(12.23±6.12) ng/ml、(13.59±5.46) ng/ml、(21.18±7.44) ng/ml、(26.61±8.82) ng/mlo NT-proBNP화galec-tin-3적수평수환자심공능적강저이승고.출원시NT-proBNP혹galectin-3잉고우정상적환자재수방중발생심력쇠갈재발주원혹사망적궤솔명현고우정상적환자;이출원시NT-proBNP화galectin-3균증고적환자기예후명현교기중일항치증고적환자차.결론 NT-proBNP화galectin-3량자균시심력쇠갈환자불량예후적독립예측지표,galectin-3연합NT-proBNP가이경호지평고CHF환자적예후.
Objective To evaluate prognostic value of N-terminal B-type brain natriuretic peptide (NT-proBNP) combined with galectin 3 of prognostic value in patients with chronic heart failure (CHF).Methods Determination of 92 cases of CHF patients on admission and at discharge plasma NT-proBNP and galectin-3 levels,then after the patients discharge we follow up 16 months and observe the internal recurrent heart failure hospitalization rate and mortality.Results In patients the heart function of New York Heart Association (NYHA) Ⅰ,Ⅱ,Ⅲ,Ⅳ level,NT-proBNP were (351.6 ± 467.5) pg/ml,(493.2 ± 411.7) pg/ml,(1 289.6 ± 737.8) pg/ml,(2 719.2 ± 1 044.1) pg/ml,galectin-3 (12.23 ± 6.12) ng/ml,(13.59± 5.46) ng/ml,(19.18 ± 7.44) ng/ml,(26.61 ± 8.82) ng/ml as well.NT-proBNP and galectin-3 levels were increased with the depression of cardiac function.The patients who had higher NT-proBNP or galectin3 levels discharged and occurred the more probability of re-hospitalization on account of heart failure or death.Compared to those patients with one of them increased,the patients whose discharge NT-proBNP and galectin-3 value were both increased with significantly poor outcome.Conclusions Both NT-proBNP and galectin-3 were independent predictors of poor prognosis in patients with heart failure.Galectin-3 combined with NT-proBNP can assess the prognosis of patients with CHF more effectively.
